Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Incidence and Prevalence Rates Of STD
4.2.2 Implementation of National Screening Programs
4.2.3 Growing Public Awareness
4.3 Market Restraints
4.3.1 Social Stigma Associated With Patients Visiting Specialized STD Clinics.
4.3.2 Stringent Regulatory Scenario for product approvals
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 ByType of Disease
5.1.1 Chlamydia
5.1.2 Gonorrhea
5.1.3 Syphilis
5.1.4 Genital herpes
5.1.5 Hepatitis B
5.1.6 HIV/AIDS
5.1.7 Human papillomavirus (HPV)
5.1.8 Others
5.2 By Type of Diagnostic Test
5.2.1 Laboratory Testing
5.2.2 Point Of Care (PoC) Testing
5.3 By Devices
5.3.1 Laboratory Devices
5.3.1.1 Thermal Cyclers - PCR
5.3.1.2 Lateral Flow Readers Immunochromatographic Assays
5.3.1.3 Flow Cytometers
5.3.1.4 Absorbance Microplate Reader - Enzyme Linked Immunosorbent Assay (ELISA)
5.3.1.5 Others
5.3.2 Point Of Care (PoC) Devices
5.3.2.1 Phone Chips (Microfluidics + ICT)
5.3.2.2 Portable/Bench Top/Rapid Diagnostic Kits
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Siemens Healthcare GmbH
6.1.2 Abbott Laboratories
6.1.3 MedMira Inc
6.1.4 Qaigen Inc
6.1.5 Danaher Corporation (Cephied)
6.1.6 F. Hoffmann-La Roche AG
6.1.7 Diasorin S.p.A
6.1.8 bioMeriuex
6.1.9 Hologic, Inc
6.1.10 Bio-Rad Laboratories, Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS